NSHBY yields 2.50% · JNJ yields 2.13%● Live data
📍 NSHBY pulled ahead of the other in Year 1
Combined, NSHBY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NSHBY + JNJ for your $10,000?
Nisshinbo Holdings Inc., together with its subsidiaries, engages in the wireless and communications, micro devices, automobile brakes, precision instruments, chemicals, textiles, and real estate businesses worldwide. The company offers wireless communication equipment, including disaster-prevention systems and surveillance systems, mobile communication equipment for shipping and automobiles, power-supply and energy equipment, and ultrasonic sensors; and micro devices, which include CMOS operational amplifiers, SAW filters, and MEMS microphones. It also manufactures and supplies friction materials, such as disc pads and brake linings, and drum and disc brakes for use in compact cars, ordinary passenger cars, sports cars, large trucks, and buses, as well as for repairs and tests in garages and dealers; and molding products, precision parts, and system equipment, as well as electronic brake systems. In addition, the company manufactures and supplies rigid polyurethane foam/wastewater treatment carriers; carbodilite, a high-performance resin additive; bipolar plates for fuel cells; and amorphous carbon products, as well as shirts, uniforms, mobilons/elastomers, and oikos products. Further, it redevelops unused plant sites; leases office and commercial facilities; and sells housing lots. The company was incorporated in 1907 and is headquartered in Tokyo, Japan.
Full NSHBY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.